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‘Science is simply common sense at its best, that is, rigidly accurate in observation, 
and merciless to fallacy in logic’ 
-Thomas Huxley 
 
 
  
  
  
ABSTRACT 
Hedgehog (HH) signaling has an important role in many physiological processes, and deregulation of 
this pathway can result in a wide range of malignancies. The aim of this thesis is to identify and 
evaluate the role of various posttranscriptional mechanisms, including alternative splicing, RNA editing 
and antisense RNAs, associated with different key components of HH signaling.   
In PAPER l, we studied the mechanism of action and biological significance of the carboxy-terminal 
truncated variant of SUFU, SUFU-ΔC, in rhabdomyosarcoma. Our investigations revealed that SUFU-
∆C mRNA was generally expressed at lower to comparable levels than SUFU-FL mRNA but the 
protein level of SUFU-∆C was very low compared with SUFUFL. SUFUΔC could repress GLI2 and 
GLI1ΔN, but not GLI1FL, transcriptional activity to the same extent as SUFUFL. Co-expression of 
GLI1-FL with SUFU-∆C in Hek293 cells indicated that SUFU-ΔC but not SUFU-FL reduced the protein 
levels of GLI1FL. Confocal microscopy revealed a co-localization of GLI1FL with SUFU-ΔC in 
aggregate structures. Moreover, knockdown of endogenous SUFU-∆C with shRNA constructs in 
RMS13 cells caused an increase in GLI1FL protein levels and up-regulation of Hedgehog signaling 
targets (PTCH1-1B and PTCH1-1C).  
In PAPER ll, we studied the prevalence and impact of GLI1 RNA editing in modulating its oncogenic 
properties. GLI1 mRNA is edited at nucleotide 2179, which results in adenosine (A) to inosine (I) 
substitution, leading to a change from Arg to Gly at position 701. This editing event is prevalent 
(around 50%) in a number of human normal tissues. However, in tumors biopsies and tumor cell lines, 
the extent of GLI1 editing is reduced. SiRNA mediated knockdown revealed both ADAR isoforms 
(ADAR1 and ADAR2) are needed for GLI1 RNA editing. Edited GLI1 has a higher capacity to activate 
most of the transcriptional targets and is less susceptible to inhibition by SUFU. Moreover, the edited 
GLI1 is less responsive to activation by the Dual-specificity Tyrosine Phosphorylation-regulated 
Kinase 1A (Dyrk1A) compared with the non-edited GLI1. Finally, we showed that GLI1 editing affects 
GLI1-dependent cellular growth.  
In PAPER lll, we unveiled the regulatory mechanisms employed by non-coding transcripts overlapping 
the GLI1 gene, GLI1AS, in normal development and carcinogenesis. GLI1AS is positioned head-to-
head with the gene encoding GLI1. The expression of the 885-nucleotide, three-exon GLI1AS RNA 
was consistently lower but concordant with GLI1. SiRNA knockdown of GLI1AS up-regulated GLI1 
and increased cellular proliferation. Overexpression of GLI1AS resulted in down-regulation of GLI1 
and the GLI1 target genes PTCH1 and PTCH2, and decreased cellular proliferation. ChIP assays 
indicate a local alteration of chromatin structure via H3K27me3 and H3K4me3 remodeling. We also 
observed a reduction in RNA polymerase II recruitment at the GLI1 promoter region upon 
overexpression of GLI1AS, which is in-line with the chromatin-remodeling phenomena. Additionally, 
GLI1 knockdown reduced GLI1AS, while GLI1 overexpression increased GLI1AS, demonstrating a 
regulatory feedback loop on GLI1/GLI1AS expression. 
In PAPER lV, we analyzed GLI1 target genes, using single molecule RNAseq, employing two 
complementary approaches, overexpression of GLI1 and edited GLI1 combined with GLI1 depletion 
using siRNAs. Gene ontology (GO) analysis revealed that GLI1 and edited GLI1 are involved in 
developmental and metabolic processes, cellular proliferation, KEGG pathways in cancer, basal cell 
carcinomas and thyroid cancer. Moreover, these candidate target genes were further filtered via the 
FANTOM5 dataset resulting in 29 targets. Validation of the 20 targets, which have a Spearman 
correlation > 0.1 with the FANTOM dataset, by qPCR indicated that 15 targets are down-regulated in 
knockdown experiments with Rh36 rhabdomyosarcoma cells. Additionally, 4 targets (FOXS1, 
SOSTDC1, LOC100507346 and SOX18) are also up-regulated in overexpression experiments with 
Rh36 cells. Moreover, knockdown of FOXS1 in Rh36 cells resulted in down-regulation of GLI1, 
highlighting a FOXS1/GLI1 regulatory loop. Finally, GLI1 knockdown and Smoothened agonist SAG 
treatment in HH signaling responsive Daoy medulloblastoma cells modulate the expression of 9 out of 
the 15 targets, including SOSTDC1 and FOXS1.  
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1 INTRODUCTION 
1.1 HEDGEHOG SIGNALING PATHWAY 
The Hedgehog (HH) signaling pathway is a highly conserved signal transduction 
cascade that was first discovered in the fruit fly (Drosophila melanogaster) (Nüsslein-
Volhard and Wieschaus, 1980) and subsequently found in vertebrates, including 
mammals (Amakye et al., 2013; Briscoe and Thérond, 2013; Robbins et al., 2012; 
Teglund and Toftgård, 2010). HH signaling is involved in a number of developmental 
and physiological processes (Briscoe and Thérond, 2013; O’Toole et al., 2009; 
Robbins et al., 2012; Teglund and Toftgård, 2010). Moreover, deregulation in this 
pathway is known to cause neoplastic transformation (Amakye et al., 2013; Epstein, 
2008; O’Toole et al., 2009; Scales and de Sauvage, 2009; Teglund and Toftgård, 
2010; Varjosalo and Taipale, 2008). Aberrant activation of the HH signaling pathway 
is involved in several types of malignant tumors, such as medulloblastoma, 
rhabdomyosarcoma, basal cell carcinoma, and pancreas, colon, stomach, lung and 
prostate cancers (Amakye et al., 2013; O’Toole et al., 2009; Scales and de Sauvage, 
2009; Teglund and Toftgård, 2010; Tostar et al., 2010). Moreover, deregulation of 
the HH pathway during embryonic development leads to severe birth defects, 
including holoprosencephaly (Haas and Muenke, 2010), polydactyly, craniofacial 
defects and skeletal malformations (Heby-Henricson, 2011; Tostar, 2010). In this 
summary I will mainly discuss about HH signaling in vertebrates. The major chain of 
events of HH signaling is summarized in Figure 1.   
1.1.1 HH Ligand production and secretion 
HH proteins are synthesized as precursors of about 45 kDa containing two domains: 
an amino-terminal (HH-N) domain (19kDa) and a carboxy-terminal (HH-C) domain 
(25 kDa) (Briscoe and Thérond, 2013; Heby-Henricson, 2011; Teglund and Toftgård, 
2010; Tostar, 2010). Precursor HH is subjected to autoproteolytic cleavage at the 
endoplasmic reticulum (ER) resulting in HH-N containing cholesterol at the carboxy-
terminal and HH-C (Briscoe and Thérond, 2013; Mann and Beachy, 2004; Perler, 
1998). Although HH signaling is mediated by HH-N, HH-C is important for the 
autoproteolytic cleavage event (Bürglin, 2008; Heby-Henricson, 2011). HH-N is 
further modified by the attachment of fatty acid groups (Long et al., 2015), important 
for proper release, extracellular movement and, hence, for its range of action 
(Briscoe and Thérond, 2013; Long et al., 2015; Mann and Beachy, 2004; Pepinsky et 
al., 1998). HH protein can travel up to 300µm in vertebrates (Briscoe and Thérond, 
2013; Robbins et al., 2012). 
In mammals there are three different HH proteins, Sonic (SHH), Indian (IHH) and 
Desert (DHH). SHH is broadly expressed and involved in the development of many 
organs (Briscoe and Thérond, 2013; Kasper et al., 2009, 2009; Teglund and 
Toftgård, 2010). IHH has been implicated in the regulation of cartilage, bone and gut 
(Briscoe and Thérond, 2013; Koziel et al., 2004; O’Toole et al., 2009), and DHH is 
involved in germ-line development (Briscoe and Thérond, 2013; Ingham and 
McMahon, 2001; Tostar, 2010). 
 2 
 
Figure 1: The Hedgehog signaling pathway (simplified). In the absence of Hedgehog 
ligand (HH), Patched (PTCH) suppresses the function of Smoothened (SMO) and thus shuts 
off all downstream processing of the HH pathway. Glioma-associated oncogene (GLI) 
transcription factor is sequestered in the cytoplasm and inactivated by Suppressor of Fused 
(SUFU). GLI can also be partially degraded into a repressor form (GLI-R), which inhibits GLI 
targets in the nucleus. HH binding to PTCH receptors relieves SMO from PTCH-mediated 
suppression, allowing SMO to translocate into the primary cilium. Activated SMO initiates 
intracellular signal transduction and ultimately activates GLI that acts on Hedgehog target 
genes. 
1.1.2 Reception of the HH signal 
In vertebrates, HH proteins interact directly with the twelve-pass transmembrane 
protein patched (PTCH). There are two PTCH homologs in humans, PTCH1 
(ubiquitously expressed) and PTCH2 (expressed in skin and testis) (Robbins et al., 
2012; Teglund and Toftgård, 2010; Tostar, 2010). In vertebrates several cell surface 
proteins can act as HH co-receptors: CAM-related/downregulated by oncogenes 
(CDO), brother of CDO (BOC), growth arrest-specific 1 (GAS1) and low-density 
lipoprotein receptor-related protein 2 (LRP2) (Beachy et al., 2010; Briscoe and 
Thérond, 2013). Hedgehog interacting protein (HHIP) is another membrane protein 
known to bind HH, though no downstream signaling is elicited from the HH-HHIP 
interaction (Tostar, 2010). Therefore, HHIP is a considered as a negative regulator 
of HH signaling since it competes with PTCH for HH binding (Tostar, 2010).  
In the absence of HH signaling PTCH is enriched in and around the primary cilium 
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(Drummond, 2012; Rohatgi et al., 2007) and inhibits Smoothened (SMO), a seven-
pass transmembrane G-protein-coupled receptor (GPCR) (Briscoe and Thérond, 
2013; Jiang and Jia, 2015; Robbins et al., 2012; Taipale et al., 2002). The primary 
cilium is essential for the transmission of HH signaling (Drummond, 2012; Rohatgi et 
al., 2007) but why this is mandatory is unclear. One possibility is that HH signaling 
requires a distinct membrane lipid composition; a number of recent studies showed 
that the ciliary membrane contains phosphatidylinositol 4-phosphate [PI(4)P)], 
whereas the ciliary base houses phosphatidylinositol 4, 5-biphosphate [PI(4,5)P2] 
(Garcia-Gonzalo et al., 2015). This differential distributions of lipids are mediated by 
inositol polyphosphate 5-phosphatase E (INPP5E) and mutations in INPP5E have 
been associated with ciliary dysfunction (Xu et al., 2016). INPP5E restricts the ciliary 
entry of HH signaling inhibitors, including GPCR 161 (Gpr161) and [PI(4,5)P2] 
interacting Tubby-like protein 3 (Tulp3) (Chávez et al., 2015; Garcia-Gonzalo et al., 
2015; Xu et al., 2016). In the absence of HH, PTCH interacts with and sequesters 
PI(4)P at the cilia. 
Upon binding of HH, PTCH undergoes conformational change and releases PI(4)P. 
Free PI(4)P directly interacts with SMO through an arginine motif in the SMO C-
terminal domain, leading to SMO activation and ciliary localization (Garcia-Gonzalo 
et al., 2015). SMO is also subjected to phosphorylation by G protein-coupled 
receptor kinase 2 (Gprk2) and subsequent dimerization (Chávez et al., 2015; Garcia-
Gonzalo et al., 2015; Jiang and Jia, 2015; Xu et al., 2016).  
1.1.3 Signaling from SMO to GLI 
In the absence of HH, SMO is localized to the membranes of intracellular, endocytic 
vesicles (Robbins et al., 2012; Teglund and Toftgård, 2010; Tostar, 2010). In 
response to HH signaling in vertebrates, SMO shuttles from these vesicles to the 
membrane of the primary cilium. Within the cilium, SMO is enriched proximally in 
association with EVC (Ellis-van Creveld syndrome protein) and EVC2 (Farzan et al., 
2008; Robbins et al., 2012). The activation of SMO results in increased recruitment 
of the negative regulator of HH signaling, Suppressor of Fused (SUFU) and the HH 
signaling associated transcription factors, Glioma associated oncogenes (GLI2 and 
GLI3) in the primary cilium (Briscoe and Thérond, 2013; Robbins et al., 2012). The 
transport of the SUFU-GLI complex through cilia is dependent in part on KIF7 
(Briscoe and Thérond, 2013; Robbins et al., 2012). Usually, in the absence of HH 
signaling GLI makes an inactive complex with SUFU (Cherry et al., 2013); but 
activated SMO causes dissociation of the GLI–SUFU complex within the cilia. 
Activated SMO is also known to initiate non-canonical HH signaling outside cilia in 
the form of GPCR signaling (Robbins et al., 2012). The transcription factor GLI 
(PARER II, III and IV) and the negative regulator SUFU (PAPER I) will be discussed 
in more detail since these are a major focus of the research presented in this thesis. 
1.1.4 The GLI transcription factors and their interaction with SUFU  
GLI-family proteins are zinc finger transcription factors associated with the HH 
signaling pathway. Three GLI paralogs have been discovered in mammals: GLI1, 
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GLI2 and GLI3 (Briscoe and Thérond, 2013; Robbins et al., 2012; Teglund and 
Toftgård, 2010). GLI1 is the first GLI factor, originally identified in glioblastoma 
containing GLI1 gene amplification (Kinzler et al., 1987; Vogelstein and Kinzler, 
2004). GLI2 and GLI3 are direct effectors of the HH signaling pathway (Kasper et al., 
2009; Robbins et al., 2012; Scales and de Sauvage, 2009; Teglund and Toftgård, 
2010), whereas GLI1 is induced as a later event to amplify the initial HH signal 
(Shimokawa et al., 2008, 2013).  
In the absence of HH signaling proteolytically cleaved versions of GLI2 and more 
often GLI3 are produced (GLI2R and GLI3R), which act as transcriptional repressors 
and bind to the same DNA consensus motif as activated GLI (Briscoe and Thérond, 
2013; Hui and Angers, 2011; Robbins et al., 2012). The limited proteasome 
mediated cleavage of GLI (GLI2 and GLI3) is controlled both by specific GLI 
phosphorylation and ubiquitination events. Protein Kinase A (PKA), Casein Kinase 1 
(CK1), and Glycogen Synthase Kinase 3 (GSK3) are responsible for GLI 
phosphorylation. In addition, GLI ubiquitination is performed by the E3 ubiquitin 
ligase, β-TrCP (Briscoe and Th érond, 2013; Hui and Angers, 2011). Another mode 
of GLI repression is mediated by SUFU, which makes a protein complex with GLI 
(Briscoe and Thérond, 2013; Hui and Angers, 2011). SUFU-GLI complex is 
sequestered in the cytoplasm rendering GLI mediated gene activation obsolete. 
Moreover, SUFU, along with KIF7, has a role in GLIR production (Hui and Angers, 
2011; Robbins et al., 2012; Teglund and Toftgård, 2010; Tostar, 2010).  
Activation of HH signaling, releases GLI from the repressive grip of SUFU. Released 
GLI (more specifically GLI2) can undergo further activation by phosphorylation, 
acetylation or sumoylation and eventually moves to the nucleus to activate target 
genes including GLI1 (Briscoe and Thérond, 2013). Moreover, GLI1 can further 
amplify the signal by inducing itself along with other targets. 
The termination of HH signaling is facilitated by proteasome mediated degradation of 
activated GLI proteins (Hui and Angers, 2011; Robbins et al., 2012). Several studies 
showed that GLI could be completely degraded by three independent ubiquitin 
pathways: cullin 3 (CUL3) mediated SPOP E3 ubiquitin ligase (CUL3/SPOP) 
(Briscoe and Thérond, 2013; Wen et al., 2010), CUL1/β-TrCP (Huntzicker et al., 
2006), and Numb/Itch mediated ubiquitination (Di Marcotullio et al., 2006).  
1.1.5 GLI targets 
GLI transcription factors directly bind to the consensus DNA binding sequence (5 ́-
GACCACCCA-3 ́) (Hallikas et al., 2006; Kinzler and Vogelstein, 1990). Both activator 
and repressor forms of GLI bind the same sequence. The canonical GLI targets 
include GLI1 (resulting in a positive feedback loop) and components of the HH 
pathways: PTCH1, PTCH2 and HHIP (Shimokawa et al., 2013a; Teglund and 
Toftgård, 2010). Additional targets of GLI include cyclin D1 (involved in cell cycle) 
(Amakye et al., 2013; Robbins et al., 2012; Scales and de Sauvage, 2009), N-Myc 
(cell cycle regulator), Bcl2 (anti-apoptosis pathway), insulin like growth factor 2 
(IGF2), vascular endothelial growth factor (VEGF), angiopoietins and SNAIL 
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(involved in the epithelial-mesenchyme transition (EMT) in cancer metastasis) 
(Amakye et al., 2013; Briscoe and Thérond, 2013; Heby-Henricson, 2011; Robbins 
et al., 2012; Scales and de Sauvage, 2009; Teglund and Toftgård, 2010). Moreover, 
there are reports of GLI targets e.g. E2F1 (involved in cell cycle progression) without 
canonical GLI binding sites (Pandolfi et al., 2015). Further studies are needed to 
dissect the broad spectrum of GLI targets (PAPER IV).  
1.1.6 HH signaling and cancer 
HH signaling is involved in many cellular processes, including cell cycle progression 
and regulation, apoptosis, cellular, tissue and organ growth, vascularization, and 
EMT (Briscoe and Thérond, 2013; O’Toole et al., 2009; Robbins et al., 2012; 
Teglund and Toftgård, 2010). Thus, aberrant activation of HH signaling can lead to 
carcinogenesis (Amakye et al., 2013; Scales and de Sauvage, 2009). Four basic 
models have been proposed for HH pathway activation in cancer (Figure 2) 
(Amakye et al., 2013; Kasper et al., 2009; Scales and de Sauvage, 2009; Teglund 
and Toftgård, 2010). 
Ligand independent constitutive activation of HH signaling (Type I) includes:  
(i) Loss-of-function mutation of negative regulators of HH signaling (tumor 
suppressor genes), e.g., loss-of-heterozygosity and/or loss-of-function 
mutation of PTCH1 in Gorlin syndrome, basal cell carcinomas (BCCs) (over 
73% of the cases), medulloblastomas and rhabdomyosarcomas; loss-of-
function mutation of SUFU observed in sporadic cases of medulloblastomas, 
BCC (8%) and Gorlin syndrome; mis-sense mutation of GLI3 in colorectal and 
pancreatic cancer (Bonilla et al., 2016; Scales and de Sauvage, 2009; 
Teglund and Toftgård, 2010). 
(ii) Gain-of-function mutation or amplification of positive regulators of HH 
signaling (proto-oncogenes), e.g. activating mutation of SMO in BCC (20%); 
GLI1 amplification in glioma, medulloblastomas and rhabdomyosarcomas 
(Kinzler et al., 1987; Northcott et al., 2009; Roberts et al., 1989; Teglund and 
Toftgård, 2010); GLI2 amplification in squamous cell carcinoma (SCC) and 
medulloblastomas (Amakye et al., 2013).  
Ligand dependent autocrine activation of HH signaling (Type II) involves 
elevated expression of HH protein leading to auto-activation of HH signaling e.g. 
lung, upper gastrointestinal tract, colorectal, prostate, breast and melanoma tumors 
(Scales and de Sauvage, 2009).  
Ligand dependent paracrine activation of HH signaling (Type III) involves 
elevated secretion of HH ligands by the tumor cells, which induces HH signaling in 
stromal cells (Type IIIa). Activated stromal cells, in turn, secrete VEGF, IGF2, Wnt, 
which drives tumor cell growth (Amakye et al., 2013; Teglund and Toftgård, 2010). 
Many of the tumor examples listed in Type II may also work by paracrine manner 
(Scales and de Sauvage, 2009). Type III can also be reverse paracrine (Type IIIb), 
where stromal cells secrete HH ligands and activate tumor cells. 
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Figure 2: Models of HH signaling pathway activation in cancer. a) Type I ligand 
independent activation of HH signaling includes loss-of-function mutation affecting negative 
regulators of HH signaling (PTCH, SUFU), gain-of-function mutation in SMO and gene 
amplification of GLI. b) Type II autocrine ligand dependent activation of HH signaling where 
tumor cells secrete HH and activate themselves. c) Type IIIa paracrine ligand dependent 
activation of HH signaling in stromal cells where HH ligands are produced and secreted by 
the tumor cells. Activated stromal cells secrete VEGF, IGF and Wnt to induce tumor growth. 
d) Type IIIb reverse paracrine ligand dependent activation of HH signaling in tumor, where 
HH ligands are produced and secreted by the stromal cells. e) Cancer stem cell model, 
where a subset of cancer cells produce HH ligands and terminally differentiate to generate 
the bulk of tumor cells. 
Cancer stem cell (CSC) model (Type IV): This is a variation of type II and III, 
where only a subpopulation of tumor cells, cancer stem cells (CSC), have self-
renewal potential (Scales and de Sauvage, 2009). A number of developmental 
pathways including HH signaling have been implicated in the CSC tumor model 
(Merchant and Matsui, 2010). CSCs can produce daughter cells that make up the 
bulk of the tumor (Amakye et al., 2013). 
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1.2 ALTERNATIVE SPLICING 
Alternative splicing (AS) is one of the most well studied post-transcriptional 
modifications, which involves alternative selection of splicing sites on precursor 
messenger RNAs (pre-mRNAs) leading to the production of multiple mature 
messenger RNAs (mRNAs) (Nieto Moreno et al., 2015). Ultimately, AS results in the 
diversity in protein production (Irimia and Blencowe, 2012; Nieto Moreno et al., 
2015). Although we know about AS events for a while, recent and rapid rise of high 
throughput transcriptome analysis revealed an ever-increasing number of AS events, 
especially in higher eukaryotes (Irimia and Blencowe, 2012; Pan et al., 2008). 
Microarray, EST-cDNA data and especially RNAseq analysis revealed that about 
95% of multi-exonic proteins undergo AS (Pan et al., 2008).  Most of AS events are 
species and tissue specific (Irimia and Blencowe, 2012; Pan et al., 2008).  
Proteins emerging from AS are associated with a number of physiological 
processes, including embryonic stem cell (ESC) differentiation (AS of FOXP1 and 
Sall4) and neurogenesis (AS of Oct2 and REST) (Irimia and Blencowe, 2012). 
Moreover, AS events are found to be associated with the development, maintenance 
and progression of different forms of cancer (David and Manley, 2010). AS has been 
implicated in all the essential carcinogenic hallmarks: anti-apoptosis (AS of Bcl-x) 
(David and Manley, 2010; Minn et al., 1996), promotion of Warburg type metabolism 
(AS of pyruvate kinase M), regulation of proto-oncogenes (AS of cyclinD1 and H-
Ras), invasion and metastasis (AS of CD44, FGFRs, Rac1, Ron and GLI1) (David 
and Manley, 2010; Lo et al., 2009).  
1.2.1 AS and HH signaling 
Splice variations of key components of HH pathway have been identified and 
characterized, which add complexity and fine-tuning on the HH signaling output.  
There are several splice variants of PTCH1, most of which occur at the 5’-end. 
PTCH1 has four distinct first exons (exon 1, 1A, 1B, and 1C), which can alternatively 
tether to exon 2 resulting in functional diversity, e.g. PTCH1-1B is lowly expressed 
compared to PTCH1-1 or PTCH1-1A but especially unregulated in BCCs 
(Shimokawa et al., 2004, 2007). There is an additional splice variant of PTCH1, 
which skips exon 10 but includes a new exon, exon 12b (Uchikawa et al., 2006). 
PTCH2 also has couple of splice variants: 3’-end splice variant producing shorter 
and different C-terminal ends (Zaphiropoulos et al., 1999), and PTCH2 with skipped 
exons 9-10 (Rahnama et al., 2004). Internal splicing events have also been reported 
for GLI2, of which one variant showed increased expression in BCCs (Speek et al., 
2006; Tojo et al., 2003). In addition, there are two reported GLI1 splice variants: 1) 
GLI1ΔN (skips exon 2 and 3), which is functionally subpar in comparison to 
canonical GLI1 (Palaniswamy et al., 2010; Shimokawa et al., 2008); and 2) tGLI1 
(deletion of the entire exon 3 and part of exon 4), which is highly expressed in 
human glioblastoma multiform (GBM) but barely detectable in normal tissues, and 
promotes glioblastoma cell migration and invasion (Carpenter and Lo, 2012; Lo et 
al., 2009). Finally, SUFU-ΔC is the C-terminal splice variant of SUFU, which contains 
a unique exon, exon 10a (contains stop codon) and has a different mechanism of 
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GLI1 repression; unlike SUFU, SUFU-ΔC reduces the GLI protein level by inducing 
GLI degradation (Tostar et al., 2012) (PAPER I).     
1.3 RNA EDITING 
RNA editing is broadly defined as a post-transcriptional modification that introduces 
changes in RNA sequences. The most obvious example of RNA editing is transfer 
RNA (tRNA) editing, which is crucial for tRNA 3D structure and function (Nishikura, 
2010). In this summary, we will mostly focus on adenosine to inosine (A→I) editing, 
which affects both messenger RNAs (mRNAs) and non-coding RNAs (ncRNAs) 
transcribed by RNA polymerase II (Farajollahi and Maas, 2010; Nishikura, 2006, 
2010, 2016). A→I editing is the most prevalent type of RNA editing in eukaryotes, 
especially higher organisms including mammals. The enzyme responsible for A→I 
editing is Adenosine Deaminase acting on RNA (ADAR) (Daniel et al., 2015a; 
Farajollahi and Maas, 2010; Nishikura, 2006, 2010, 2016) (Figure 3).  
 
Figure 3: Domain structure and the function of ADARs. a) ADARs catalyze the hydrolytic 
deamination of adenosine (A) to inosine (I), which is read as a guanosine (G) by the 
translational machinery. b) All three ADARs (ADAR1, 2 & 3) have a C-terminal catalytic 
domain and double stranded RNA binding domains (dsRBD). ADAR1 has additional Z-DNA 
binding domains (Za, Zb) at the N-terminal end. R, arginine/lysine rich domain. 
1.3.1 Functional implications of A→I editing 
Physiological and pathophysiological implications of A→I editing are widespread and 
include: amino acid sequence changes, e.g. Arginine (R) to Glycine (G) substitution 
in GLI1 at position 701 (Shimokawa et al., 2013) and Glutamine (Q) to Arginine (R) 
substitution in glutamate receptor-2 (GluR-2) at position 607 (Li and Church, 2013); 
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modification of splicing events by altering splicing junction sequences, e.g. A→I 
editing in Protein Tyrosine Phosphatase Non-Receptor Type 6 (PTPN6) resulting in 
retention of an extra intron (Deffit and Hundley, 2016); alteration of microRNA 
(miRNA) biogenesis by introducing change in the stem-loop structure of precursor 
miRNAs (pre-miRNA), which can modify the interaction with miRNA biogenesis 
components, including Dicer, Drosha, DGCR8 and TRBP (Deffit and Hundley, 2016; 
Nishikura, 2016), e.g. editing of pri-miRNA-142 blocks its processing by the Drosha–
DGCR8 complex (Nishikura, 2016; Yang et al., 2006); interference of miRNA-mRNA 
interactions, e.g. A→I editing  at 3’-UTR of the Rho GTPase activating protein 26 
(ARHGAP26) disrupts binding of miR-30b-3p and miR-573 preventing gene 
silencing (Deffit and Hundley, 2016; Kawahara et al., 2007; Wang et al., 2013) 
(Figure 4).  
Recent studies showed the importance of A→I editing in mammalian brain 
development especially in the regulation of neurotransmission, neural differentiation 
and maturation (Daniel et al., 2015a; Li and Church, 2013). RNA editing is also 
important in cancer development (Nishikura, 2010, 2016; Paz et al., 2007). Results 
of a global bioinformatic analysis with Alu sequence RNA editing showed significant 
hypoediting in various types of human cancers (Paz et al., 2007), which suggest that 
a reduction of A→I editing may be involved in the pathogenesis of cancer (Paz et al., 
2007).  
1.3.2 Adenosine Deaminase acting on RNA (ADAR) 
ADAR catalyzes the hydrolytic deamination of adenosine (A) to inosine (I) and the 
translational machinery reads inosine (I) as a guanosine (G) (Deffit and Hundley, 
2016; Farajollahi and Maas, 2010; Nishikura, 2010, 2016). The first mammalian 
ADAR gene, ADAR1, was originally discovered in humans (Farajollahi and Maas, 
2010; Nishikura, 2016), followed by the identification of two additional homologs, 
ADAR2 and ADAR3. The adenosine deaminase activity of ADAR1 and ADAR2 has 
been shown by many groups, but no incident of ADAR3 mediated editing has been 
reported, although the functional domain in ADAR3 appears to be intact (Farajollahi 
and Maas, 2010; Nishikura, 2016). The expression of ADAR1 and ADAR2 is 
ubiquitous and mostly present in the nucleus; ADAR3 is only found in the brain 
(Farajollahi and Maas, 2010; Nishikura, 2016). Additionally, the ADAR proteins are 
conserved among vertebrates. Each ADAR has several splice variants that differ on 
intracellular localization, target specificity and extend of enzymatic activity (Deffit and 
Hundley, 2016; Farajollahi and Maas, 2010; Nishikura, 2016). 
The domain structure is very similar amongst the human ADARs (Figure 3b). All 
three ADARs have a single C-terminal catalytic deaminase domain containing Zn-Fe 
at the catalytic center. They also have multiple double stranded RNA binding 
domains (dsRBDs), which indicate that the functionality of the ADAR depends on the 
3D structure, more specifically the hairpin loop of the target RNA (substrate) (Daniel 
et al., 2015a; Nishikura, 2016). The longest isoform of ADAR1, p150, has Z-DNA 
binding domains at the N-terminal end, indicating possible additional functionality or 
targets specify (Farajollahi and Maas, 2010; Nishikura, 2010) (Figure 3). Inactive 
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ADAR3 has a ‘N-terminal arginine/lysine rich R-domain’ of unknown function. The 
functionality of ADAR1 and ADAR2 depends on dimer formation. ADAR 1 and 
ADAR2 can form both homodimers (ADAR1-ADAR1 or ADAR2-ADAR2) and an 
heterodimer (ADAR1-ADAR2), although the ADAR heterodimer is considered 
inactive by many researchers (Nishikura, 2016).  
 
Figure 4: Functional implication of RNA editing. a) RNA editing in the exons can result in 
coding sequence change e.g. Arg to Gly at position 701 of GLI1. b) RNA editing can either 
diminish or introduce splice sites resulting in splicing variations. c) RNA editing at the 3’ 
UTRs can alter the interaction between mRNA and miRNA. d) RNA editing can affect 
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miRNA processing by altering pre-miRNA secondary structures. 
ADAR targets must have a stem loop structure of >20 nucleotides (Daniel et al., 
2015a). The extent of editing depends on both the size of the loop and the number of 
mismatches within the loop (Daniel et al., 2015b). Moreover, most of the editing 
targets are preferentially edited by either ADAR1 or ADAR2, e.g., glutamate 
receptor-2 (GluR-2) is specifically edited by ADAR2; functional serotonin (5-HT) 
receptor-2C has five editing events, two of which are specifically edited by ADAR1 
(Burns et al., 1997; Li and Church, 2013). Some targets can be edited by both 
ADAR1 and 2, e.g., GLI1 editing at 701 (Shimokawa et al., 2013), three of the five 
specific editing events in 5-HT receptor-2C (Li and Church, 2013; Marcucci et al., 
2011; Peng et al., 2006).  
 
Figure 5: Mechanism of RNA editing of GLI1. Inverted Alu sequence present in intron 11 
of the GLI1 pre-mRNA can produce a stem-loop structure. ADARs can bind the stem-loop 
and introduce A-to-I editing at a specific A residue at exon 12. 
1.3.3 A→I editing site specificity  
A→I editing of a target sequence is very specific. Moreover, the extent of editing can 
also vary.  A recent transcriptome analysis of the brain showed that different RNA 
editing target sites can have different editing efficiency (Li et al., 2009), e.g., in 
human brain the editing efficiency of GLI1 at position 701 is about 50% (Shimokawa 
et al., 2013), meaning that 50% of the GLI1 mRNA in the brain is edited. Recent 
studies showed that in humans both the specificity and extent of A→I editing is 
directly related to the presence of inverted Alu elements in introns and in UTRs 
(untranslated regions) (Daniel et al., 2014, 2015a, 2015b). Inverted Alu elements 
produce stem-loop structures, which attract the recruitment of ADARs; ADARs can, 
in turn, edit intronic Alu stem-loop and/or adjacent exons resulting in changes in the 
exonic sequence and abolish or introduce new splice sites (Daniel et al., 2015b). 
Human GLI1 is edited at exon 12 and contains inverted Alu elements at intron 11; on 
the contrary mouse GLI1, which has only one Alu element at intron 11 and incapable 
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of producing a stem-loop, is not edited (Daniel et al., 2014) (Figure 5). Even if 
inverted Alu elements directed RNA editing can explain the approximate location of 
A→I editing events, still the exact sequence position of an editing event can not be 
rationalized, e.g., why GLI1 is edited at position 701, why not any other adenosines 
(A) surrounding position 701?     
1.4 LONG NON-CODING RNA 
Long non-coding RNAs (lncRNAs), as the name implies, are diverse class of long 
(~200nt) RNAs, which have no long open reading frame (ORF) and are not 
translated into proteins (Ulitsky and Bartel, 2013; Villegas and Zaphiropoulos, 2015; 
Wang and Chang, 2011; Zhao et al., 2015). LncRNAs are a new class of RNA, 
which are increasingly appreciated due to the rapid emergence of high-throughput 
transcriptome sequencing. It is estimated that the prevalence of lncRNAs can be as 
much as 90% of the total transcriptome, whereas protein coding mRNAs only 
account for roughly 2% (Bánfai et al., 2012; Esteller, 2011; Fatica and Bozzoni, 
2014; Quinn and Chang, 2016). The most well established example of lncRNAs is 
the X inactive specific transcript (XIST) eliciting X chromosome inactivation (Penny 
et al., 1996). lncRNAs are involved in a number of biological processes including 
RNA mediated genome imprinting by chromatin modification (Fatica and Bozzoni, 
2014; Geisler and Coller, 2013; Pelechano and Steinmetz, 2013; Villegas and 
Zaphiropoulos, 2015), RNA degradation (Gong and Maquat, 2011) or stabilization 
(Faghihi et al., 2008; Fatica and Bozzoni, 2014; Geisler and Coller, 2013), 
translational repression and allosteric regulation of enzymatic activity (Geisler and 
Coller, 2013). LncRNAs are also found to be associated with cellular differentiation, 
development and disease (Esteller, 2011; Fatica and Bozzoni, 2014). Even though 
the biogenesis of lncRNAs is well established and has no considerable difference 
from protein coding mRNAs (Quinn and Chang, 2016), little is known about their 
functional role and mechanism of action.  
1.4.1 Classification of lncRNAs 
LncRNAs can be classified based on their location in the genome or mode of action. 
According to location lncRNAs are broadly divided into two groups; intergenic 
lncRNAs, sandwiched between two protein coding genes; and overlapping RNAs, 
which overlap with an often protein coding gene (Pelechano and Steinmetz, 2013; 
Quinn and Chang, 2016; Villegas and Zaphiropoulos, 2015). The overlap is more 
often than not in a head-to-head arrangement; but in rare occasions tail-to-tail or 
head-to-tail arrangements can also be found (Mahmoudi et al., 2009; Villegas and 
Zaphiropoulos, 2015). Antisense RNAs, defined as overlapping head-to-head or tail- 
to-tail, influence the expression of sense RNAs, which are often protein coding, by 
modulating their transcription rate, mRNA stability, transport or translation efficiency 
(Mahmoudi et al., 2009; Pelechano and Steinmetz, 2013; Villegas and 
Zaphiropoulos, 2015; Villegas et al., 2014; Yap et al., 2010). According to the 
literature, about 70% of transcripts have antisense partners (Pelechano and 
Steinmetz, 2013). The level of expression of antisense RNAs is often very low 
compared with the sense transcript (Pelechano and Steinmetz, 2013; Villegas and 
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Zaphiropoulos, 2015; Villegas et al., 2014). 
In addition, lncRNAs can be divided into several groups based on their biological 
roles. Firstly, transcriptional regulatory lncRNAs are nuclear lncRNAs involved in 
transcriptional regulation of target genes as transcription activators or repressors 
(Blackledge et al., 2015; Fatica and Bozzoni, 2014; Holoch and Moazed, 2015). This 
type of lncRNAs can act in cis and/or trans (Blackledge et al., 2015; Fatica and 
Bozzoni, 2014; Holoch and Moazed, 2015). A second group of lncRNAs intervenes 
at post-transcriptional and translational levels (Geisler and Coller, 2013; Ulitsky and 
Bartel, 2013; Villegas and Zaphiropoulos, 2015). Their functions range from 
influencing the stability of target RNAs to modulating the translational outcome. 
Unlike transcriptional regulatory lncRNAs, post-transcriptional regulatory lncRNAs 
can function both in the nucleus and the cytoplasm (Geisler and Coller, 2013). 
Finally, a vast majority of lncRNAs have no known function and may be considered 
as products of transcriptional noise (Fatica and Bozzoni, 2014; Quinn and Chang, 
2016).  
1.4.2 LncRNA-mediated transcriptional regulation 
As mentioned earlier, nuclear functional lncRNAs can module transcriptional 
outcome in cis and/or trans. Cis-acting nuclear lncRNAs can be intergenic or 
overlapping to the target gene (Holoch and Moazed, 2015; Quinn and Chang, 2016). 
Moreover, they can act both as repressors or activators (Blackledge et al., 2015; 
Holoch and Moazed, 2015). LncRNAs often work as scaffolds for chromatin 
remodeling complexes and via RNA-DNA interactions with their target gene, 
promote either transcriptional repression or activation (Blackledge et al., 2015; 
Pelechano and Steinmetz, 2013; Wang and Chang, 2011) (Figure 6).  
Transcriptional repressor lncRNAs (Figure 6a and 6b) often employ chromatin 
imprinting complexes, like DNA methyltransferases 3 (DNMT3) (Fatica and Bozzoni, 
2014; Rinn et al., 2007; Zhao et al., 2008), the polycomb repressive complexes 
(PRC1and PRC2), histone H3 lysine 9 (H3K9) methyltransferase, resulting in an 
increase of DNA and histone methylation especially at promoters, e.g. histone H3 
lysine 9 di/tri-methylation (H3K9me2/3) and/or H3 lysine 27 di/tri-methylation 
(H3K27me2/3) (Fatica and Bozzoni, 2014; Rinn et al., 2007; Zhao et al., 2008). 
Example of cis-acting repressor lncRNAs include X inactive specific transcript (XIST) 
(Nozawa et al., 2013; Penny et al., 1996; Schoeftner et al., 2006; Zhao et al., 2008), 
AIRN, antisense to IGF2R (insulin-like growth factor 2 receptor RNA) gene (Latos et 
al., 2012; Sleutels et al., 2002) and GLI1AS, antisense to GLI1 (Villegas et al., 2014) 
(PAPER III). The most well studied trans-acting repressor lncRNA is the HOXA 
transcript antisense RNA (HOTAIR), which represses the expression of HOXD 
genes (Rinn et al., 2007; Wang and Chang, 2011). HOTAIR can work as a scaffold 
to recruit two different distinct repressive complexes, PRC2 and the H3K4 
demethylating complex KDM1A–coREST–REST on the same genomic region 
(Fatica and Bozzoni, 2014; Rinn et al., 2007; Tsai et al., 2010). A hallmark of 
repressor lncRNAs is the increase of promoter methylation, H3K9me2/3 and 
H3K27me2/3, and the reduced recruitment of RNA polymerase II at the locus of 
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action (Fatica and Bozzoni, 2014; Holoch and Moazed, 2015; Wang and Chang, 
2011).   
 
Figure 6: Chromatin modification by lncRNAs. LncRNAs can act as transcription 
repressors by recruiting repressor protein complexes like PRC2 and H3K9-
methyltransferace to cis or trans targets (a and b). LncRNAs can also act as transcriptional 
activators (c and d). 
Transcriptional activator lncRNAs (Figure 6c and 6d) are less studied compared 
with repressor lncRNAs. Cis-acting transcriptional activator lncRNAs, also known as 
enhancer RNAs (eRNAs) (Ørom et al., 2010), can activate neighboring genes by 
recruiting chromatin activation complexes, including the MLL1 complex, a multi-
protein complex that mediates both histone H3 trimethylation at lysine 4 (H3K4me3) 
and histone H4 acetylation at lysine 16 (H4K16ac), which are associated with 
transcriptionally active genes (Bertani et al., 2011; Fatica and Bozzoni, 2014; Wang 
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et al., 2011). An example of an eRNA is HOTTIP, which is encoded at the distal 5’ 
end of the HOXA locus (Wang et al., 2011). HOTTIP eRNA binds at the HOTTIP 
locus and brings it closer to HOXA genes by facilitating chromosome looping. 
HOTTIP eRNA recruits MLL1 complex at the HOXA locus, which results in an 
increase of H3K4me3 leading to the recruitment of RNA polymerase II (Wang et al., 
2011). We do not know much about trans-acting eRNAs; a rare example of a trans-
acting eRNA is JPX, which binds to the transcriptional repressor CTCF, inhibiting its 
binding to the XIST promoter, thus activating XIST transcription (Sun et al., 2013). 
1.4.3 Post-transcriptional and translational regulation elicited by lncRNAs 
LncRNAs also have complex post-transcriptional and translational modes of action 
and are known to influence target RNAs by affecting their splicing pattern, RNA 
stability, RNA editing, translational efficiency and last but not least, may function as 
sponges for microRNA (miRNA) (Figure 7) (Fatica and Bozzoni, 2014; Geisler and 
Coller, 2013; Pelechano and Steinmetz, 2013; Ulitsky and Bartel, 2013; Villegas and 
Zaphiropoulos, 2015; Wang and Chang, 2011).  
 
Figure 7: Function and compartmentalization of lncRNAs. Nuclear lncRNAs can induce 
chromatin modification (a and b) and affect splicing events of target mRNA (c).  Cytoplasmic 
lncRNAs can increase the stability of target mRNAs by inhibiting mRNA degradation 
machinery (d), alter mRNA-miRNA interactions (e) or can act as miRNA sponge (f). 
LncRNA affects splicing: Antisense RNAs can form complete or partial RNA-RNA 
duplexes with overlapping target mRNAs, which can inhibit the recruitment of the 
splicing machinery leading to alternative splicing of target mRNA, e.g., ‘natural 
antisense transcript against MYC’ inhibits MYC intron-1 splicing (Krystal et al., 1990). 
RNA-RNA duplexes also have the potential to affect target mRNA editing events by 
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inhibiting ADAR (adenosine deaminase acting on RNA) (Geisler and Coller, 2013). 
LncRNA modulates target mRNA stability: RNA-RNA duplex formation with an 
antisense lncRNA can affect the stability of the target sense mRNA. Wrap53, the 
antisense RNA to p53, increases p53 mRNA stability. siRNA mediated knockdown 
of wrap53 dramatically reduce the stability of p53 (Mahmoudi et al., 2009).  
LncRNA affects miRNA binding to target mRNA: LnRNA and target mRNA RNA-
RNA duplexes can rescue miRNA mediated translational repression, e.g. an RNA-
RNA duplex between BACE1AS (antisense lncRNA to BACE1) with BACE1 (beta-
site APP-cleaving enzyme 1) mRNA stabilizes BACE1 mRNA by blocking miRNA 
(miR-485-5p) induced repression (Faghihi et al., 2008, 2010). Moreover, lncRNAs 
can also act as cytoplasmic sponges for miRNAs, indirectly increasing mRNA 
stability, e.g. PTEN-pseudogene antisense transcript can act as a sponge for 
miRNAs targeting PTEN mRNA (Poliseno et al., 2010). An additional recent example 
of an miRNA sponge is the CDR1AS/CiRS7 non-coding circular RNAs (crRNAs), 
which acts as sponge for miR-7 (Memczak et al., 2013).   
LncRNA mediated translational up-regulation/down-regulation: Antisense UCHL1 
lncRNA up-regulates UCHL1 protein production via a SINE2B repeat element-
mediated translational up-regulation (Carrieri et al., 2012). On the other hand, some 
lncRNA-mRNA duplexes can increase target mRNA decay, e.g. down-regulation of 
SERPINE1 (Gong and Maquat, 2011).   
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2 AIMS OF THE THESIS 
The general goal of my PhD study is to dissect the HH signaling pathway for a better 
understanding of its role in carcinogenesis. More specifically, we are interested to 
identify and evaluate the role of various posttranscriptional mechanisms, including 
alternative splicing, RNA editing and antisense RNAs, in modulating the HH 
signaling output.   
Specific aims: 
1) Investigate the mechanism of action and biological significance of SUFU splice 
variants in rhabdomyosarcoma. 
 
2) Unveil the regulatory mechanisms employed by non-coding transcripts 
overlapping the GLI1 in normal development and carcinogenesis. 
 
3) Determine the prevalence and impact of GLI1 RNA editing events in modulating 
its oncogenic properties for carcinogenic growth.  
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3 RESULTS AND CONCLUSIONS 
3.1 PAPER I 
Novel mechanism of action on hedgehog signaling by a suppressor of fused 
carboxy terminal variant 
SUFU protein (also known as SUFU-Full length) is 484 amino acid long (Stone et 
al., 1999). Apart from SUFU-Full length (SUFU-FL), a carboxy-terminal deleted 
isoform was identified in human, known as SUFU-∆C, which is 433 amino acid long 
(Stone et al., 1999). These two isoforms of SUFU are the result of splicing 
variation. The SUFU gene  (chromosome 10q24-25) contains 12 exons (Grimm et 
al., 2001; Stone et al., 1999) and in SUFU-FL all 12 exons are included but SUFU-
∆C incorporates only the first 10 exons and then uses a stop codon from a unique 
exon 10a (present in intron 10). Thus, SUFU-∆C shares identical amino acid 
sequence with SUFU-FL up to amino acid 432 and identical nucleotide sequence 
up to base pair 1442 (Stone et al., 1999; Tostar et al., 2012).  
Our investigations revealed that SUFU-∆C mRNA was generally expressed at 
lower levels than SUFU-FL in all cell types tested except in the lung cell line, 
GI117. Moreover, we detected comparable level of SUFU-∆C and SUFU-FL mRNA 
in the rhabdomyosarcoma (RMS) cell lines, CCA and RMS13. However, the protein 
level of SUFU-∆C was very low compared with SUFU-FL in RMS cell lines, which 
indicates that SUFU-∆C protein may be unstable. Additionally, heterologous 
expression of the SUFU variants in the Hek293 cell line was in agreement with a 
reduced stability of SUFU-ΔC relative to SUFU-FL in human RMS cells. Moreover, 
treatment with the proteasome inhibitor MG-132 conferred a selective increase of 
both the endogenous and exogenous SUFU-ΔC but still not reaching the levels of 
SUFU-FL, suggesting the involvement of additional mechanisms, possibly 
lysosomal autophagy (Gao et al., 2010).  
Biochemical analysis upon overexpression revealed that SUFU-ΔC could repress 
GLI2 and GLI1ΔN, but not GLI1FL, transcriptional activity to the same extent as 
SUFU-FL. SUFU and GLI1 bind to each other using both N-terminal and C-terminal 
regions of the two proteins (Dunaeva et al., 2003; Merchant et al., 2004). Since 
SUFU-ΔC could not act as an equally efficient repressor as SUFU-FL, a role of the 
last 51 amino acids of SUFU in the repression on GLI1FL may be suggested. 
Moreover, under conditions of activated HH signaling SUFU-ΔC was more effective 
than SUFU-FL in inhibiting GLI1ΔN. Importantly, co-expression of GLI1FL with 
SUFU-∆C in Hek293 cells indicated that SUFU-ΔC but not SUFU-FL reduced the 
protein levels of GLI1-FL. These findings suggest that the mechanism of inhibition 
of GLI1FL by SUFU-ΔC may be fundamentally different from SUFU-FL, and could 
involve an increased degradation of the GLI1FL protein. Interestingly, the levels of 
GLI2 remained unchanged in the same transfection setting, highlighting the 
specificity of the GLI1FL and SUFU-ΔC interaction. Additionally, the levels of 
endogenous GLI1FL in RMS13 cells were investigated following transfection of the 
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SUFU variants. SUFU-ΔC, in contrast to SUFU-FL, conferred a detectable 
reduction of the GLI1FL levels. Moreover, the proteasome inhibitor MG-132 
increased the GLI1FL protein in both SUFU-ΔC and SUFU-FL transfected cells. 
Additionally, confocal microscopy revealed a co-localization of GLI1FL with SUFU-
ΔC but not SUFU-FL in aggregate structures.  
ShRNA mediated knockdown SUFU-∆C in RMS13 cells resulted in an increase of 
GLI1FL protein but not mRNA levels. SUFU-∆C knockdown also resulted in the 
transcriptional up-regulation of the Hedgehog signaling targets, PTCH1-1B and 
PTCH1-1C. The knockdown experiments indicate that endogenous SUFU-ΔC can 
modulate HH signaling activity by reducing GLI1FL protein levels, and this is 
different to the mechanism of action of SUFU-FL. 
In conclusion, our study  suggests the presence of novel regulatory controls in the 
HH signaling pathway, which are elicited by the distinct mechanism of action of the 
two alternative spliced SUFU proteins. 
3.2 PAPER II 
RNA editing of the GLI1 transcription factor modulates the output of 
Hedgehog signaling 
A previous high throuput screening revealed that RNA editing is a frequent post-
transcriptional event and a large number of mRNAs, including GLI1, are edited in the 
brain (Li et al., 2009). In our study, we confirmed that GLI1 mRNA is edited at 
nucleotide 2179, resulting in adenosine (A) to inosine (I) substitution. This A to I 
substitution leads to a change from Arginine to Glycine at position 701 of the GLI1 
protein. The prevalence of this GLI1 editing event is about 50% in a number of 
human tissues including cerebellum (both fetal and adult), skin, pancreas, ovary and 
colon. However, in the corresponding tumor cell lines the extent of GLI1 editing was 
negligible. Moreover, the reduction in RNA editing of GLI1 was not limited to cancer 
cell lines but also occurred in BCC biopsy specimens compared to control skin 
samples. These findings indicate that GLI1 RNA editing is a normal physiological 
event, which is disrupted during cancer development. This is in-line with previous 
findings highlighting a global down-regulation of RNA editing in cancer cells (Paz et 
al., 2007). GLI1 RNA editing in normal cells implies that this post-transcriptional 
modification may act as a “protective barrier” that has to be overcome in the process 
of tumorigenesis. 
In order to address the role of ADARs in GLI1 editing we performed siRNA 
mediated knockdown experiments in neuroblastoma cell lines (SK-N-AS, SH-
SY5Y, SK-N-BE(2) and SK-N-SH). The level of GLI1 editing was reduced upon the 
knockdown of ADAR1 or ADAR2, which indicates that both ADAR isoforms are 
needed for GLI1 RNA editing. One scenario that could provide a mechanistic 
interpretation of this finding may be the formation of ADAR1/ADAR2 heterodimers 
that are catalytically active on this substrate. 
Biochemical experiments showed that edited GLI1, GLI1-701G, has a higher 
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capacity to activate most of the transcriptional targets tested, including 12xGLIBS-luc 
and mPtch1-1B-luc reporters. In addition, GLI1-701G is less susceptible to inhibition 
by the negative regulator of HH signaling, SUFU. 
Confocal microscopy analysis revealed no diferences in edited and non-edited GLI1 
cellular localization. Moreover, the GLI1-701G was less responsive compared with 
GLI1 to activation elicited by the Dual-specificity Tyrosine Phosphorylation-regulated 
Kinase 1A (Dyrk1A). Finally, we showed that GLI1 editing affected GLI1-dependent 
cellular growth.  
In summary, our findings demonstrated that post-transcriptional modification of GLI1 
at the level of RNA editing modulates the biological outcomes of HH signaling.  
3.3 PAPER III 
Identification of novel non-coding RNA-based negative feedback regulating 
the expression of the oncogenic transcription factor GLI1 
In this project, using in silico analysis of EST databases we have identified a 
polyadenylated non-coding transcript, GLI1AS, on the opposite (antisense) strand of 
the GLI1 gene in a head-to-head orientation. Rapid Amplification of cDNA Ends 
(RACE) in Rh36, CCA and RMS13 cancer cells determined the sequence of GLI1AS 
RNA, which is 885-nucleotide long and has three exons. 
Expression analysis of GLI1AS and GLI1 in different cancer cell lines (PC3, 22Rv1 
PANC1, A549, AGS, D283Med, RMS13, RD, Rh36, and CCA) showed concordant 
regulation between GLI1 and GLI1AS. Moreover, the expression of GLI1AS RNA in 
cancer cells lines, BCC and breast tumor samples was consistently lower but 
concordant with GLI1 mRNA expression. Splicing pattern analysis using GLI1AS 
exonic and intronic PCR primer sets revealed that splicing of intron 1 is more 
frequent than intron 2, meaning that intron 2 is retained in the final transcript more 
often than intron 1, suggesting a possible functional implication of the retained 
sequences. Analysis of RNA expression in nuclear/cytoplasmic fractionations of 
RMS cells (Rh36, CCA and RMS13) revealed that unspliced GLI1AS RNAs are 
preferentially retained in the nucleus, whereas spliced GLI1AS RNAs are transported 
to the cytoplasm.  
In order to address possible biological roles of GLI1AS, we performed siRNA-
mediated knockdown in Rh36 and CCA cells. Knockdown of GLI1AS resulted in 
GLI1 expression up-regulation. Moreover, GLI1AS knockdown induced cell 
proliferation of Rh36 cells. Since proliferation of Rh36 cells is GLI1 dependent 
(Tostar et al., 2010), the effect of GLI1AS on cell proliferation may be mediated 
through changes of GLI1 expression. Reciprocally, transfection of siRNAs targeting 
GLI1 in the Rh36 and CCA cells resulted in a decrease of GLI1AS levels. Thus, 
depletion of one member of the GLI1/GLI1AS pair has opposing effects on the other 
partner; GLI1 knockdown reduces GLI1AS but GLI1AS knockdown increases GLI1. 
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To examine whether the endogenous modulation of GLI1 and GLI1AS levels in 
Rh36 cells has an impact on tumor growth, the CAM xenograft model was used 
(Tostar et al., 2012; Villegas et al., 2014). Treatment of Rh36 cells with GLI1 siRNAs 
decreased their capacity to form tumors in this model. On the other hand an 
increased tumor weight was observed following treatment with GLI1AS siRNAs. 
We also performed GLI1AS overexpression analysis in Rh36 cells to validate the 
GLI1AS knockdown experiments. Overexpression of GLI1AS resulted in the down-
regulation of both GLI1 RNA and protein expression, as well as of the GLI1 target 
genes PTCH1 and PTCH2. Moreover, the expression of the INHBE gene, which is 
tail-to-tail with GLI1AS, was also reduced, while the expression of the 
unrelated ADAR2 gene was unaffected. GLI1AS overexpression also reduced 
Rh36 cellular proliferation. It is interesting to note that overexpression of either the 
“5’-terninal half” or the “3’-terninal half” of GLI1AS did not affect GLI1 expression or 
the proliferative capacity of the transfected Rh36 cells. Consequently, in order to 
function as a GLI1 repressor the complete RNA sequence of GLI1AS is needed, 
which suggests to a possible 3D folding of GLI1AS, acting as a scaffold to recruit 
repressor protein complexes, similarly to other lncRNAs (Latos et al., 2012; 
Poliseno et al., 2010; Rinn et al., 2007). 
 
 
Figure 8: Proposed mechanism for the GLI1AS mediated transcriptional repression of 
the GLI1 and INHBE genes. The INHBE GLI1AS and GLI1 genes are indicated by arrows. 
‘P’ highlights promoter regions. 
In order to address the GLI1AS scaffold hypothesis we performed chromatin 
immunoprecipitation (ChIP) assays using antibodies against chromatin remodeling 
markers. Overexpression of GLI1AS increased the recruitment of repression marker, 
H3K27me3, in the INHBE/GLI1AS/GLI1 genomic regions. H3K27me3 is often 
associated with the recruitment of polycomb repressive complex 2 (PRC2). This 
finding is in agreement with the observations on other non-coding RNA mediated 
repression mechanisms (Johnsson et al., 2013; Modarresi et al., 2012). We also 
observed a reduction in RNA polymerase II recruitment at the GLI1 promoter region 
upon overexpression of GLI1AS, which is in-line with the chromatin-remodeling 
phenomena. Surprisingly, GLI1AS overexpression also increased the chromatin 
activation marker H3K4me3 in the INHBE/GLI1AS/GLI1 locus.  
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Activation of HH signaling by the Smoothened agonist SAG in Daoy 
medulloblastoma cells increased not only GLI1 but also GLI1AS expression. 
Similarly, treatment of pancreatic adenocarcinoma PANC1 cells with TGFβ, a GLI1 
inducer in this cellular context, increased not only GLI1 but also GLI1AS expression.  
In conclusion, our study showed an additional layer of GLI1 regulation, apart from 
splice variations and GLI1 RNA-editing, which is mediated by a non-coding RNA.  
3.4 PAPER IV  
Global analysis of GLI1 and RNA-edited GLI1 target genes 
Even though GLI1 is a transcription factor associated with HH signaling and acts as 
an oncogene (Nilsson et al., 2000), very little is known on the GLI1 targets, apart 
from a few target genes, including GLI1, PTCH1, PTCH2 and HHIP. In this study, we 
analyzed the GLI1 global targets by overexpressing both canonical and edited GLI1, 
as well as by knocking down GLI1 expression. We focused at both common and 
differentially regulated targets of edited/non-edited GLI1. 
Single molecule RNAseq was used following overexpression/depletion in the 
rhabdomyosarcoma Rh36 cell line. Genes with reciprocally changed expression in 
the overexpression/depletion experiments were considered as likely true target 
genes.  Combining the selected genes of the GLI1 or the GLI1-701G overexpression 
with those of the GLI1 depletion resulted in 477 and 480 genes regulated by non-
edited/edited GLI1, respectively, 197 of which were common in the two datasets. 
Gene ontology (GO) analysis using the common 197 genes revealed that both 
edited and non-edited GLI1 are associated with cellular proliferation, which is in-line 
with our previous findings (Shimokawa et al., 2013). Non-edited/edited GLI1 are also 
linked to KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways in cancer, 
BCC and thyroid cancer. 
Candidate target genes were further filtered via the FANTOM5 dataset of global 
gene expression in 833 tissues (FANTOM Consortium and the RIKEN PMI and 
CLST (DGT) et al., 2014) resulting in 29 targets. Validation of the 20 targets, which 
have a Spearman correlation > 0.1 with the FANTOM dataset, by qPCR indicated 
that 15 targets (excluding PTCH1) are down-regulated in biological replicates of 
knockdown experiments in Rh36 cells. Additionally, out of these 15, 4 targets 
(FOXS1, SOSTDC1, LOC100507346 and SOX18) are also up-regulated in 
biological replicates of overexpression experiments in Rh36 cells.  
Moreover, knockdown of FOXS1 in the same cells resulted in down-regulation of 
GLI1, highlighting a FOXS1/GLI1 regulatory loop.  
Finally, GLI1 knockdown and Smoothened agonist SAG treatment in HH signaling 
responsive Daoy medulloblastoma cells modulate the expression of 9 out of the 15 
targets, including SOSTDC1 and FOXS1. 
In conclusion, this study identified and validated novel non-edited/edited GLI1 target 
genes using both overexpression and knockdown. 
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4 FUTURE PROSPECTIVE 
4.1 ELABORATING ON THE MECHANISM OF GLI1AS 
In PAPER III we successfully showed the transcriptional repressor function of 
GLI1AS on GLI1 and the neighboring gene, INHBE employing the chromatin-
repressing marker H3K27me3. The next logical step would be to dissect the 
mechanism of action of GLI1AS even further. Based on the findings of PAPER III, it 
is quite reasonable to speculate on the involvement of PRC2 in the GLI1AS 
mediated transcriptional repression process. A member of possible experimental 
approaches can be employed to address the of involvement of PRC2 including, 1) 
the effect of siRNA knockdown of the components of the polycomb repressive 
complex PRC2 (siEZH1, siEZH2 and siEED) on GLI1AS mediated repression; 2) 
DZNep (3-Deazaneplanocin A, HCl, a well known inhibitor of the polycomb 
component EZH2) treatment of Rh36 cells upon overexpression of GLI1AS; and 
finally, 3) RNA ChIP or PAR-CLIP (Photoactivatable-Ribonucleoside-Enhanced 
Crosslinking and Immunoprecipitation) (Hafner et al., 2010; Spitzer et al., 2014) 
using antibodies against components of PRC2.  
In PAPER III, we also showed the importance of the complete sequence of the 
GLI1AS lncRNA in the GLI1 and INHBE repression process, which may imply the 
significance of the 3D folding of GLI1AS. A number of recent publications 
demonstrated that lncRNAs can work as scaffolds to recruit chromatin modifiers at 
loci of interest (Johnsson et al., 2013; Latos et al., 2012; Rinn et al., 2007). In light of 
all these finding, it is important to address critical regions of GLI1AS by deletion 
analysis and clarify possible DNA binding motifs of GLI1AS using modern 
techniques, including PAR-CLIP and/or ChIRP (Chromatin Isolation by RNA 
Purification) (Chu et al., 2011). Moreover, a recent article (Holdt et al., 2013) 
suggested that the Alu elements of ANRIL, a non-coding RNA, confer its ability to 
recognize global targets. Interestingly, intron 2 and exon 3 of GLI1AS are mainly 
composed of Alu sequences. Consequently, analyzing the possible functionality of 
the GLI1AS Alu elements might shed light on the mode of action of GLI1AS. Last but 
not least, a global analysis can also be performed to identify possible trans-targets of 
GLI1AS. 
4.2 DIFFERENTIAL TARGET OF EDITED AND NON-EDITED GLI1 
In PAPER IV, we analyzed the GLI1 and GLI1-701G common targets. It would be 
interesting to address targets differentially regulated by edited/non-edited GLI1 and 
validate them by qRCR analysis. Moreover, to address the direct targets of 
edited/non-edited GLI1, GLI1 ChIP-seq (Chromatin Immunoprecipitation followed by 
DNA sequencing) can be performed using Rh36 cell line over-expressing 
edited/non-edited GLI1. Another important step could be address the role GLI1 
editing in the SHH-responsive human medulloblastoma cell line, Daoy. Endogenous 
GLI1 editing (Arginine to Glycine at position 701) can be introduced in Daoy cells 
using CRISPR/Cas9 (Ran et al., 2013) technology. This could be followed by RNA-
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seq and ChIP-seq upon SHH signaling induction to assess differences in the HH 
signaling response depending on the editing status of endogenous GLI1.   
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